Antibody engineering know-how

June 5, 2013
Antibody engineering know-how
Credit: IgG and engineered recombinant antibody fragments

(Medical Xpress)—Antibodies are of enormous value to society as therapeutic and diagnostic agents. There are many scientists worldwide interested in producing their own novel engineered antibody based molecules as part of their research work.

Scientists from UCD Conway Institute and UCD Centre have published an accessible instruction manual detailing how to make antigen binding molecules for molecular studies and translational research.

This protocol published in the journal Nature Protocols describes the design and development of recombinant antigen-binding molecules from through rapid identification and cloning of variable genes.

Describing the work, Conway scientist Dr David O'Connell said, "The protocol is accessible for groups not specialised in this area, and allows them to carry out reverse engineering of functional, recombinant antigen-binding molecules from hybridomas within 50 working days.

We are delighted with this publication and view it an endorsement by a prestigious scientific journal of our experience in the engineering of . It reflects our capabilities in antibody design, construction and characterisation that are made possible through the excellent infrastructure available on the university campus."

This research reflects a successful collaboration between UCD scientists with CRO Genscript Inc. The team, which also includes Conway Fellow, Professor Gil Lee hopes to attract new collaborators with both industry and academia on foot of this work.

More information: Nat Protoc. 2013 May 16;8(6):1125-48. doi: 10.1038/nprot.2013.057. Epub 2013 May 16.

Related Stories

New stable antibodies created

June 29, 2012

(Medical Xpress) -- Australian scientists have overcome one of the most pressing problems facing the pharmaceutical industry – how to create antibodies that are stable enough to meet stringent requirements necessary ...

Peptides for the treatment of severe diseases

April 15, 2013

A new class of drugs for the treatment of severe diseases such as cancer and autoimmune diseases is developed by the start-up Bicycle Therapeutics. The company is generating bicyclic peptides that can selectively bind disease-related ...

Reducing experimental inflammatory arthritis

May 24, 2013

(Medical Xpress)—UCD researchers led by Conway Fellow, Professor David Brayden in UCD School of Veterinary Medicine have successfully reduced inflammation in the swollen arthritic knees of a murine model using a novel nanoparticle.

Recommended for you

A cheaper, high-performance prosthetic knee

July 30, 2015

In the last two decades, prosthetic limb technology has grown by leaps and bounds. Today, the most advanced prostheses incorporate microprocessors that work with onboard gyroscopes, accelerometers, and hydraulics to enable ...

Flow means 'go' for proper lymph system development

July 27, 2015

The lymphatic system provides a slow flow of fluid from our organs and tissues into the bloodstream. It returns fluid and proteins that leak from blood vessels, provides passage for immune and inflammatory cells from the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.